Krystal Biotech, Inc. (KRYS) Reports Next Week: Wall Street Expects Earnings Growth

Core Insights - Krystal Biotech, Inc. (KRYS) is expected to report a year-over-year increase in earnings and revenues for the quarter ended September 2025, with consensus estimates predicting earnings of $1.12 per share (+23.1%) and revenues of $91.5 million (+9.1%) [1][3] Earnings Expectations - The earnings report is scheduled for November 3, and the stock may rise if actual results exceed expectations, while a miss could lead to a decline [2] - The consensus EPS estimate has been revised 15.22% higher in the last 30 days, indicating a positive reassessment by analysts [4] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Krystal Biotech is lower than the consensus estimate, resulting in an Earnings ESP of -1.18%, which indicates a bearish outlook [12] - The company currently holds a Zacks Rank of 3 (Hold), complicating predictions of an earnings beat [12] Historical Performance - In the last reported quarter, Krystal Biotech exceeded the consensus EPS estimate of $1.08 by delivering earnings of $1.29, resulting in a surprise of +19.44% [13] - Over the past four quarters, the company has beaten consensus EPS estimates three times [14] Industry Comparison - In the Zacks Medical - Biomedical and Genetics industry, Alnylam Pharmaceuticals (ALNY) is expected to post earnings of $1.67 per share for the same quarter, reflecting a significant year-over-year change of +434% and revenues of $1.02 billion (+104%) [18][19] - Alnylam's consensus EPS estimate has been revised 43.6% higher in the last 30 days, and it has an Earnings ESP of +25.79%, suggesting a likely earnings beat [19][20]